Key Stats for Allogene Therapeutics Stock
- Price change for Allogene Therapeutics stock: 12%
- $ALLO Share Price as of Apr. 13: $3
- 52-Week High: $4
- $ALLO Stock Price Target: $7
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Allogene Therapeutics (ALLO) stock surged on Monday after the company reported highly encouraging interim data from its ALPHA3 trial.
- The results showed that 58.3% of patients treated with cema-cel achieved MRD negativity, compared to just 16.7% in the observation arm.
- That’s a 41.6% absolute difference, well above the 25%-30% benchmark the company set as clinically meaningful.
MRD, or minimal residual disease, measures whether tiny amounts of cancer remain after treatment. Clearing MRD has been shown to strongly predict whether patients will stay in remission.
The ALPHA3 trial is testing whether intervening earlier, before patients actually relapse, can improve long-term outcomes in large B-cell lymphoma.
The safety data was just as important as the efficacy numbers.
- Ten of the twelve patients treated with cema-cel were managed entirely as outpatients after infusion.
- There were no cases of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
- That’s a striking contrast to standard CAR T therapy, where roughly 70% to 90% of patients require hospitalization for toxicity management.
This is a big deal because one of the biggest barriers to CAR T adoption has been the intense management these therapies typically require. If CEMA-CEL can be delivered safely in an outpatient setting, it opens the door to community cancer centers, not just major academic hospitals.
That’s already happening. Community centers accounted for about 33% of the cema-cel infusions in the trial, including sites with little to no prior CAR T experience.
Allogene Therapeutics stock is rallying in part because investors see this as evidence that the company’s off-the-shelf allogeneic approach can scale in ways traditional CAR T therapies cannot.
Unlike conventional CAR T, which requires harvesting and engineering a patient’s own cells, cema-cel is manufactured in advance and available immediately, like a standard biologic drug.
That makes it dramatically easier to administer, especially in community settings.
The company now expects to complete enrollment in the trial by year-end 2027. An interim event-free survival analysis is expected in mid-2027, with a primary readout in mid-2028.
If positive, these results could support a regulatory filing.
See analysts’ growth forecasts and price targets for Allogene Therapeutics stock (It’s free) >>>
What the Market Is Telling Us About Allogene Therapeutics Stock
Allogene Therapeutics stock hit a 52-week high on today’s data.
The MRD clearance results, clean safety profile, and real-world feasibility data together represent the clearest clinical validation the company has reported to date.
With a cash runway into early 2028, Allogene Therapeutics stock now has meaningful catalysts ahead.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Allogene Therapeutics Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
